Loading clinical trials...
Loading clinical trials...
A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-sirolimus) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
Conditions
Interventions
nab-Sirolimus
Locations
9
United States
Stanford University Medical Center
Palo Alto, California, United States
Sarcoma Oncology Research Center
Santa Monica, California, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
October 1, 2015
Primary Completion Date
November 1, 2021
Completion Date
April 1, 2022
Last Updated
April 7, 2023
Lead Sponsor
Aadi Bioscience, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions